CD8A and breast neoplasm: That PA-mL7N significantly outperformed anti-PD-1 in curbing tumor growth in the 4T1 syngeneic mouse breast tumor model by blocking the PD-1/PD-L1 interaction and promoting CD8+ T-cell recruitment highlights its potential as a peptide immune checkpoint blocker for cancer treatment.